Thalidomide (1) was developed in the 1950's as a nontoxic sedative/hypnotic drug, but was withdrawn from the market in the early 1960's because of its serious teratogenicity. [1] [2] [3] [4] [5] However, it was subsequently identified as an effective agent for the treatment of multiple myeloma (MM), AIDS, Hansen's disease, and various cancers. [1] [2] [3] [4] [5] The US Food and Drug Administration (FDA) approved it for the treatment of erythema nodosum in Hansen's disease in 1998, and (in combination with dexamethasone) for the treatment of MM in 2006. Official approval for the use of thalidomide (1) to treat MM has also been applied for in Japan. Thalidomide (1) has been discovered to have various biological activities, including inhibition of tumor necrosis factor-a (TNF-a) production, and anti-inflammatory, anti-angiogenic, and cyclooxygenase (COX)-inhibitory activities.
Concerning the former two activities, thalidomide (1), 5-OHThal (2a) and N-OH-Thal (2c) all exhibit comparable activity. [7] [8] [9] However, tubulin polymerization-inhibitory activity was observed only for the hydroxylated metabolites (2a, 2c), and thalidomide (1) lacks this activity. 6) These results prompted us to investigate comprehensively the biological activities of hydroxylated metabolites of thalidomide.
Thalidomide (1) is metabolically labile, and many metabolites have been identified or proposed, [10] [11] [12] [13] [14] [15] [16] [17] including seven hydroxylated metabolites, 2a-g (Fig. 1) . Hydroxylation is reported to occur mainly at the 5-position in the phthaloyl moiety and the 5Ј-position in the glutarimide moiety, 10) although the 4-position of the phthaloyl moiety and the nitrogen atom of the imide ring can also be hydroxylated (Fig.  1) . 10) 5-OH-Thal (2a), N-OH-Thal (2c) [11] [12] [13] and cis-5Ј-OHThal (cis-2f) [14] [15] [16] have been well-characterized and their methods of preparation have been reported in detail. For 4-OH-Thal (2b), trans-5Ј-OH-Thal (trans-2f), and the dihydroxylated metabolites, 5,N-di-OH-Thal (2d), 4,N-di-OHThal (2e), and 5,5Ј-di-OH-Thal (2g), neither spectroscopic data nor any detailed description of their synthesis is available in the literature, to our knowledge. In addition, the reported synthetic method of cis-5Ј-OH-Thal (cis-2f) via free g-hydroxyglutamic acid is unsatisfactory, because some of the intermediates are sticky and intractable, the overall yield is not so high, and the stereochemistry is difficult to control. We therefore sought to establish methods for systematic preparation of all of the proposed metabolites, 2a-g. In this paper, we describe the synthesis of the mono-and dihydroxylated metabolites of thalidomide (2a-g), as well as the results of chemical/physical characterization and evaluation of their TNF-a production-inhibitory activity.
Chemistry
Hydroxylated metabolites 2a-e were synthesized as shown in Chart 1.
Boc-glutamine 3 was treated with 1,1Ј-carbonyldiimidazole (CDI) in the presence of a catalytic amount of 4-dimethylaminopyridine (DMAP) to afford the cyclic imide 4.
heated to 200°C for 2 h without solvent to give the corresponding anhydrides 11a and 11b, respectively. These compounds were treated with 5 or 8 in the presence of EDCI and HOBt to afford 12a-e, except 12c which was prepared from 13. The benzyl group of 12a-e was removed by catalytic hydrogenation with H 2 gas on 10% Pd/C to afford the hydroxylated thalidomide derivatives 2a-e.
5Ј-Hydroxylated metabolites [5Ј-OH-Thal (2f) and 5Ј,Ndi-OH-Thal (2g)] were synthesized as shown in Chart 2.
Trans-N-Boc-L-hydroxyproline 14 was treated with aqueous ammonia (28%) in the presence of EDCI and HOBt as coupling reagents to give the carboxamide 15. 19 21, 22) but the desilylated product was formed as a by-product. Although several kinds of alkaline hydrolysis were tried, e.g., with KOH and NaOH, the by-product was always formed to some extent. Compound 18 was cyclized using CDI in the presence of a catalytic amount of DMAP to afford the glutarimide derivative 19. The Boc group was selectively removed in the presence of TBDMS ether with TFA/CH 2 Cl 2 to afford 20 as the TFA salt. 23) Careful reaction of 20 and phthalic anhydride in the presence of EDCI and HOBt at 0°C for 30 min afforded only the cis-isomer 21 (epimerization may occur at this step). When the reaction time was extended to 2 d at room temperature, epimerization occurred to afford a ca. 1 : 1 mixture of cis-and trans-isomers. Trans-5Ј-OTBDMS-thalidomide 24 was isolated by recrystallization. Interestingly, cis-5Ј-acetoxythalidomide was reported to be more crystallizable than trans-5Ј-acetoxythalidomide. 14) Therefore, the crystallizability may depend on the nature of the 5Ј-hydroxyl substituent. Finally, removal of the TBDMS group of 21 with tetra-nbutylammonium fluoride (TBAF) at 0°C gave the desired cis-5Ј-OH-Thal (cis-2f) stereoselectively. Trans-5Ј-OH-Thal (trans-2f) was also prepared by means of a procedure similar to that used for cis-5Ј-OH-Thal (cis-2f). Although it was not clear whether the 3Ј or 5Ј position was epimerized, probably the two were not epimerized simultaneously, judging from the large optical rotation values (see Experimental). This synthetic route is economical, and allows stereo-controlled preparation of cis-5Ј-OH-Thal (cis-2f). 5Ј-OH-Thal's (cisand trans-2f) thus obtained were optically unstable, i.e., this compound epimerizes rapidly to a 1 : 1 mixture of cis-and trans-isomers under heating at 100°C (data not shown).
TNF-a a Production-Inhibitory Activity TNF-a is one of the cytokines mediating immune regulation, and has a wide range of activities extending beyond the well-characterized pleiotropic pro-inflammatory properties to include diverse signaling for cell differentiation, proliferation and death. 24, 25) The growing understanding of the pathophysiological role of TNF-a in various diseases, including tumors, as well as the discovery of the TNF-a production-inhibitory activity of thalidomide (1), 26) has led researchers to regard this activity as the molecular basis for the pharmacological effects elicited by thalidomide (1). 27) Although thalidomide (1) has recently been found to be a multi-target drug, [1] [2] [3] [4] [5] TNF-a production-regulating activity is still regarded as one of the major molecular mechanisms of thalidomide's action, 1) and the drug is recognized as an immunomodulatory agent. Because thalidomide (1) is a metabolically labile compound, as mentioned before, the question of whether its metabolites retain this activity or not is of great interest.
For this reason, we investigated the TNF-a production-inhibitory activity of the hydroxylated metabolites of thalidomide (2a-g) by means of the previously reported method, using a human monocytic leukemia cell line, THP-1. 28, 29) THP-1 cells do not produce TNF-a under normal cell culture conditions, but do produce TNF-a in response to 12-Otetradecanoylphorbol 13-acetate (TPA).
30,31) Thalidomide (1) shows moderate TNF-a production-inhibitory activity in this assay system. [1] [2] [3] [4] [5] 28, 29) The TNF-a production-inhibitory activity of test compounds was measured as described in the experimental section as %-inhibition values, i.e., 100% and 0% represent complete inhibition and no inhibition, respectively. Of course the %-values were variable from experiment to experiment, but the order of efficacy was reproducible. A typical set of data collected at the test compound concentration of 30 mM is presented in Table 1 .
The mother compound, thalidomide (1) showed moderate TNF-a production-inhibiting activity (64.1% inhibition at 30 mM), in accordance with our previous reports. 28, 29) Monohydroxylation at the phthalimide/aromatic moiety [5-OHThal (2a) and 4-OH-Thal (2b)] caused loss of the activity (Ϫ2.1-6.2%). Mono-hydroxylation at the nitrogen atom of the glutarimide ring [N-OH-Thal (2c)] decreased the activity, though the compound showed weak TNF-a production-inhibitory activity (29.7% inhibition). On the other hand, mono-hydroxylation at the 5Ј-position of the glutarimide moiety [5Ј-OH-Thal (cis-2f and trans-2f)] slightly enhanced the activity (72.1-74.0% inhibition). The cis-and trans-isomers (cis-2f and trans-2f) showed almost the same efficacy, possibly because of easy isomerization (vide supra).
Interestingly, although both mono-hydroxylation at the phthalimide/aromatic moiety [5-OH-Thal (2a) and 4-OH-Thal (2b)] and at the nitrogen atom in the glutarimide moiety [N-OH-Thal (2c)] caused loss or decrease of the activity, double hydroxylation at these sites [5,N-di-OH-Thal (2d) and 4,Ndi-OH-Thal (2e)] retained or enhanced the activity (69.8-90.9% inhibition). 5,N-di-OH-Thal (2d) showed the most potent activity among the compounds examined. It was far more potent than thalidomide (1), with an IC 50 value of 3.7 mM in our assay system (TNF-a production inhibition was almost complete at 30 mM, as shown in Table 1 ). Another di-hydroxylated analog, 5,5Ј-di-OH-Thal (2g), showed moderate TNF-a production-inhibitory activity (53.1% inhibition), which is weaker than that of thalidomide (1) or cis-and trans-5Ј-OH-Thal (cis-and trans-2f), but more potent than that of 5-OH-Thal (2a).
These results indicate that metabolic hydroxylation of thalidomide (1) can result in loss, retention, decrease or increase of TNF-a production-inhibitory activity. Therefore, it is not easy to predict the influence of the metabolism of thalidomide (1) on the TNF-a production-inhibitory activity in particular in vivo situations. Further studies to investigate the influence of metabolism on other biological activities of thalidomide are under way.
Experimental General

1
H-NMR spectra were obtained on a JEOL JNM-a 500 spectrometer (500 MHz). Mass spectra were obtained on a JEOL JMA-HX 110 spectrometer with m-nitrobenzyl alcohol. Melting points, determined on a Yanaco MP-J3 micro melting point apparatus are uncorrected. Optical rotation was measured by JASCO DIP-1000. Flash column chromatographies were performed on silica gel 60 Kanto Kagaku (40-100 mm).
tert-Butyl 2,6-Dioxopiperidin-3-ylcarbamate (4) To a solution of BocGln-OH 3 (10.0 g, 40.6 mmol) in dry THF (100 ml) was added 1,1Ј-carbonyldiimidazole (CDI) (7. Table 1 . TNF-a Production-Inhibitory Activity of Thalidomide (1) and Its Hydroxylated Metabolites (2a-g) at 30 mM
Compound
TNF-a production-inhibitory activity (%) 
4-Benzyloxyphthalic Acid (10a)
To a solution of 4-hydroxyphthalic acid 9a (5.00 g, 27.5 mmol) in 1.7 mol/l aqueous KOH (80 ml, 138 mmol) was added benzyl chloride (3.80 g, 30.0 mmol). The reaction mixture was stirred at 120°C for 12 h. After the reaction mixture had cooled, 2.0 mol/l aqueous HCl was added to it until the product precipitated. The precipitate was collected by filtration and washed with toluene twice, affording 10a (8.23 g, quant.) as a white solid. This was used for the next reaction without purification. 
3-Benzyloxyphthalic Acid (10b)
To a solution of 3-hydroxyphthalic anhydride 9b (2.00 g, 12.2 mmol) in 2 mol/l aqueous KOH (30 ml, 60 mmol) was added benzyl chloride (1.65 g, 13.0 mmol). The reaction mixture was stirred at 120°C for 10 h. After cooling, the mixture was acidified by addition of 2.0 mol/l aqueous HCl, and extracted 5 times with CHCl 3 /MeOH. The organic layer was washed with brine, dried over MgSO 4 , filtered and concentrated to afford 10b (2.54 g, 9.34 mmol, 77%) as a white solid. This was used for the next reaction without purification. Benzyloxy-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (12b) This compound was obtained as a white solid (89% yield), in a manner similar to that described for the preparation of 12a from 11b and 5. -2-(1-benzyloxy-2,6-dioxopiperidin-3-yl)isoindoline-1,3 dione (12d) This compound was obtained as a white amorphous solid (74% yield), in a manner similar to that described for the preparation of 12a from 11a and 8. -2-(1-benzyloxy-2,6-dioxopiperidin-3-yl)isoindoline-1,3 dione (12e) This compound was obtained as a white amorphous solid (30% yield), in a manner similar to that described for the preparation of 12a from 11b and 8. 
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5-Hydroxy-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (2a) (5-OH-Thal)
To a solution of 12a (590 mg, 1.62 mmol) in AcOH (15 ml) and AcOEt (40 ml) was added 10% Pd-C (260 mg), and the mixture was stirred at room temperature under an H 2 atmosphere for 1 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The residue was purified by flash column chromatography (hexane : AcOEtϭ3 : 1 to 0 : 1 v/v) to afford 2a (260 mg, 0.949 mmol, 59%) as a white powder. mp Ͼ300°C. 
4-Hydroxy-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (2b) (4-OH-Thal)
To a solution of 12b (500 mg, 1.37 mmol) in MeOH (10 ml) and DMF (10 ml) was added 10% Pd-C (50 mg), and the mixture was stirred at room temperature under an H 2 atmosphere for 4 h, then filtered through Celite, and concentrated. The residue was purified by flash column chromatography (hexane : AcOEtϭ2 : 3 v/v) to afford 2b (320 mg, 1.17 mmol, 85%) as a yellow powder. mp 281-282°C. (2S,4R)-tert-Butyl-2-carbamoyl-4-hydroxypyrrolidine-1-carboxylate  (15) To a solution of (2S,4R)-1-tert-butoxycar-bonyl-4-hydroxypyrrolidine-2-carboxylic acid 14 (4.90 g, 21.2 mmol) in dry CH 3 CN (60 ml) was added EDCI · HCl (4.89 g, 25.5 mmol) and HOBt · H 2 O (3.45 g, 25.5 mmol) at 0°C. The mixture was stirred at room temperature for 6 h, then cooled to 0°C, and 28% aqueous ammonia (6 ml) was carefully added. Stirring was continued at 0°C for 30 min and then at room temperature for 1 h. Insoluble material was removed by filtration, then the filtrate was concentrated and purified by flash column chromatography (CHCl 3 Cells and Measurement of TNF-a a THP-1 cells were maintained as previously described. 28, 29) The exponentially growing cells in RPMI1640 medium supplemented with 10% v/v fetal bovine serum (1.0ϫ10 6 cells/ml) were treated or not treated with 10 nM TPA at 37°C under a 5% CO 2 atmosphere for 18 h in 24-well multiplates. To test the effects of compounds, cells were treated with TPA (10 nM) in the presence or absence of a test sample at 30 mM. Then the cells were collected by centrifugation (1500 rpmϫ10 min). The amount of TNF-a in the supernatant was measured by the use of TNF-a Human Biotrak Easy ELISA (Amersham Biosciences, RPN5967) according to the supplier's protocol. The concentration of TNF-a produced by THP-1 cells treated with 10 nM TPA alone was approximately 100 pg/ml under these experimental conditions. The assay was performed at least three times. The results were basically reproducible and a typical set of data (mean values of duplicate) obtained at the same time is presented in Table 1 .
